{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:22:02Z","timestamp":1762161722690,"version":"3.37.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T00:00:00Z","timestamp":1636156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-021-00770-4","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T13:02:33Z","timestamp":1636203753000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Highlights in clinical medicine\u2014Giant cell arteritis, polymyalgia rheumatica and Takayasu\u2019s arteritis: pathogenic links and therapeutic implications"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9698","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Solimando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Dammacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,6]]},"reference":[{"key":"770_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/ard.16.2.230","volume":"16","author":"HS Barber","year":"1957","unstructured":"Barber HS. Myalgic syndrome with constitutional effects; polymyalgia rheumatica. Ann Rheum Dis. 1957;16:230\u20137.","journal-title":"Ann Rheum Dis"},{"key":"770_CR2","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56:506\u201315.","journal-title":"Rheumatology (Oxford)"},{"key":"770_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","volume":"13","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Brouwer E, Mason JC, et al. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13:578\u201392.","journal-title":"Nat Rev Rheumatol"},{"key":"770_CR4","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442\u201358.","journal-title":"JAMA"},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/art.21699","volume":"55","author":"D Blockmans","year":"2006","unstructured":"Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55:131\u20137.","journal-title":"Arthritis Rheum"},{"key":"770_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/OPTH.S243203","volume":"14","author":"R Dammacco","year":"2020","unstructured":"Dammacco R, Alessio G, Giancipoli E, et al. Giant cell arteritis: the experience of two collaborative referral centers and an overview of disease pathogenesis and therapeutic advancements. Clin Ophthalmol. 2020;14:775\u201393.","journal-title":"Clin Ophthalmol"},{"key":"770_CR7","doi-asserted-by":"publisher","first-page":"845","DOI":"10.7326\/0003-4819-77-6-845","volume":"77","author":"P Fauchald","year":"1972","unstructured":"Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatic. Clinical and biopsy findings. Ann Intern Med. 1972;77:845\u201352.","journal-title":"Ann Intern Med"},{"key":"770_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra011913","volume":"347","author":"C Salvarani","year":"2002","unstructured":"Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261\u201371.","journal-title":"N Engl J Med"},{"key":"770_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1586\/eci.10.59","volume":"6","author":"P Ghosh","year":"2010","unstructured":"Ghosh P, Borg FA, Dasgupta B. Current understanding and management of giant cell arteritis and polymyalgia rheumatica. Expert Rev Clin Immunol. 2010;6:913\u201328.","journal-title":"Expert Rev Clin Immunol"},{"key":"770_CR10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454\u201361.","journal-title":"Arthritis Rheum"},{"key":"770_CR11","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1212\/WNL.0000000000001409","volume":"84","author":"D Gilden","year":"2015","unstructured":"Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;84:1948\u201355.","journal-title":"Neurology"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","volume":"16","author":"M Samson","year":"2017","unstructured":"Samson M, Corbera-Bellalta M, Audia S, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017;16:833\u201344.","journal-title":"Autoimmun Rev"},{"key":"770_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/ken294","volume":"48","author":"M Cutolo","year":"2009","unstructured":"Cutolo M, Cimmino MA, Sulli A. Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford). 2009;48:93\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"770_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"770_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/1756-185X.13288","volume":"22","author":"TA Kermani","year":"2019","unstructured":"Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis. 2019;22(Suppl 1):41\u20138.","journal-title":"Int J Rheum Dis"},{"key":"770_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79:19\u201330.","journal-title":"Ann Rheum Dis"},{"key":"770_CR17","doi-asserted-by":"crossref","unstructured":"Serra R, Butrico L, Fugetto F, et al. Updates in Pathophysiology, Diagnosis and Management of Takayasu Arteritis. Annals of Vascular Surgery [Internet]. 2016 [cited 2021 Aug 30];35:210\u201325. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509616303715","DOI":"10.1016\/j.avsg.2016.02.011"},{"key":"770_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.semarthrit.2018.05.002","volume":"48","author":"TA Kermani","year":"2019","unstructured":"Kermani TA, Diab S, Sreih AG, et al. Arterial lesions in giant cell arteritis: a longitudinal study. Semin Arthritis Rheum. 2019;48:707\u201313.","journal-title":"Semin Arthritis Rheum"},{"key":"770_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10238-020-00668-7","volume":"21","author":"F Dammacco","year":"2021","unstructured":"Dammacco F, Cirulli A, Simeone A, et al. Takayasu arteritis: a cohort of Italian patients and recent pathogenetic and therapeutic advances. Clin Exp Med. 2021;21:49\u201362.","journal-title":"Clin Exp Med"},{"key":"770_CR20","doi-asserted-by":"publisher","first-page":"621098","DOI":"10.3389\/fimmu.2020.621098","volume":"11","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Ohtsuki S, Berry GJ, et al. Innate and adaptive immunity in giant cell arteritis. Front Immunol. 2020;11:621098.","journal-title":"Front Immunol."},{"key":"770_CR21","doi-asserted-by":"publisher","first-page":"136042","DOI":"10.1172\/JCI136042","volume":"131","author":"K Jin","year":"2021","unstructured":"Jin K, Wen Z, Wu B, et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J Clin Invest. 2021;131:136042.","journal-title":"J Clin Invest"},{"key":"770_CR22","first-page":"E970","volume":"114","author":"H Zhang","year":"2017","unstructured":"Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci U S A. 2017;114:E970\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"770_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50\u20137.","journal-title":"N Engl J Med."},{"key":"770_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2019.01.049","volume":"73","author":"H Zhang","year":"2019","unstructured":"Zhang H, Watanabe R, Berry GJ, et al. CD28 Signaling controls metabolic fitness of pathogenic T cells in medium and large vessel vasculitis. J Am Coll Cardiol. 2019;73:1811\u201323.","journal-title":"J Am Coll Cardiol"},{"key":"770_CR25","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788\u201398.","journal-title":"Arthritis Rheum"},{"key":"770_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/annrheumdis-2012-202883","volume":"73","author":"M Corbera-Bellalta","year":"2014","unstructured":"Corbera-Bellalta M, Garc\u00eda-Mart\u00ednez A, Lozano E, et al. Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. Ann Rheum Dis. 2014;73:616\u201323.","journal-title":"Ann Rheum Dis"},{"key":"770_CR27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","volume":"121","author":"J Deng","year":"2010","unstructured":"Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906\u201315.","journal-title":"Circulation"},{"key":"770_CR28","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/art.34327","volume":"64","author":"B Terrier","year":"2012","unstructured":"Terrier B, Geri G, Chaara W, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 2012;64:2001\u201311.","journal-title":"Arthritis Rheum"},{"key":"770_CR29","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1080\/14397595.2019.1570999","volume":"29","author":"A Kurata","year":"2019","unstructured":"Kurata A, Saito A, Hashimoto H, et al. Difference in immunohistochemical characteristics between Takayasu arteritis and giant cell arteritis: It may be better to distinguish them in the same age. Mod Rheumatol. 2019;29:992\u20131001.","journal-title":"Mod Rheumatol"},{"key":"770_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00393-020-00809-z","volume":"79","author":"S Arnold","year":"2020","unstructured":"Arnold S, Holl Ulrich K. Lamprecht P [Pathogenesis of large vessel vasculitides]. Z Rheumatol. 2020;79:505\u201315.","journal-title":"Z Rheumatol"},{"key":"770_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MD.0b013e3181af70c1","volume":"88","author":"K Maksimowicz-McKinnon","year":"2009","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88:221\u20136.","journal-title":"Medicine (Baltimore)"},{"key":"770_CR32","doi-asserted-by":"publisher","unstructured":"Hellmich B, \u00c1gueda AF, Monti S, et al. Treatment of Giant Cell Arteritis and Takayasu Arteritis\u2014Current and Future. Curr Rheumatol Rep [Internet]. 2020 [cited 2021 Jul 20]; 22: 84. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11926-020-00964-x","DOI":"10.1007\/s11926-020-00964-x"},{"key":"770_CR33","doi-asserted-by":"crossref","unstructured":"Spanish GCA Study Group, Italian GCA Study Group, Turkish Takayasu Study Group, Vasculitis Clinical Research Consortium, Carmona FD, Coit P, et al. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep [Internet]. 2017 [cited 2021 Jul 20];7:43953. Available from: http:\/\/www.nature.com\/articles\/srep43953","DOI":"10.1038\/srep43953"},{"key":"770_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/BF02229647","volume":"15","author":"A Uddhammar","year":"1996","unstructured":"Uddhammar A, Sojka BN, Rantap\u00e4\u00e4-Dahlqvist S. HLA antigens in polymyalgia rheumatica in northern Sweden. Clin Rheumatol. 1996;15:486\u201390.","journal-title":"Clin Rheumatol"},{"key":"770_CR35","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.yexmp.2015.12.007","volume":"100","author":"DJ Pisapia","year":"2016","unstructured":"Pisapia DJ, Lavi E. VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. Exp Mol Pathol. 2016;100:114\u20135.","journal-title":"Exp Mol Pathol"},{"key":"770_CR36","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1128\/JCM.02438-08","volume":"47","author":"F Njau","year":"2009","unstructured":"Njau F, Ness T, Wittkop U, et al. No correlation between giant cell arteritis and Chlamydia pneumoniae infection: investigation of 189 patients by standard and improved PCR methods. J Clin Microbiol. 2009;47:1899\u2013901.","journal-title":"J Clin Microbiol"},{"key":"770_CR37","doi-asserted-by":"publisher","unstructured":"Arnaud L, Cambau E, Brocheriou I, et al. Absence of Mycobacterium tuberculosis in Arterial Lesions from Patients with Takayasu\u2019s Arteritis. J Rheumatol [Internet]. 2009 [cited 2021 Jul 20];36:1682\u20135. Available from: http:\/\/www.jrheum.org\/lookup\/doi\/https:\/\/doi.org\/10.3899\/jrheum.080953","DOI":"10.3899\/jrheum.080953"},{"key":"770_CR38","doi-asserted-by":"publisher","unstructured":"Byrd AL, Segre JA. Adapting Koch\u2019s postulates. Science [Internet]. 2016 [cited 2021 Jul 20];351:224\u20136. Available from: https:\/\/www.sciencemag.org\/lookup\/doi\/https:\/\/doi.org\/10.1126\/science.aad6753","DOI":"10.1126\/science.aad6753"},{"key":"770_CR39","doi-asserted-by":"crossref","unstructured":"Watanabe R. Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology [Internet]. 2020 [cited 2021 Aug 4];59:e46\u20137. Available from: https:\/\/academic.oup.com\/rheumatology\/article\/59\/9\/e46\/5864208","DOI":"10.1093\/rheumatology\/keaa253"},{"key":"770_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","volume":"22","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Berry GJ, Liang DH, et al. Pathogenesis of giant cell arteritis and takayasu arteritis-similarities and differences. Curr Rheumatol Rep. 2020;22:68.","journal-title":"Curr Rheumatol Rep"},{"key":"770_CR41","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1002\/cti2.1332","volume":"10","author":"M Samson","year":"2021","unstructured":"Samson M, Greigert H, Ciudad M, et al. Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. Clin Transl Immunology. 2021;10:e1332.","journal-title":"Clin Transl Immunology."},{"key":"770_CR42","doi-asserted-by":"crossref","unstructured":"Schacke H. Mechanisms involved in the side effects of glucocorticoids. Pharmacology and Therapeutics [Internet]. 2002 [cited 2021 Oct 14];96:23\u201343. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725802002978","DOI":"10.1016\/S0163-7258(02)00297-8"},{"key":"770_CR43","first-page":"203","volume":"14","author":"W Ericson-Neilsen","year":"2014","unstructured":"Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203\u20137.","journal-title":"Ochsner J"},{"key":"770_CR44","doi-asserted-by":"publisher","unstructured":"Ng MKC. Glucocorticoid treatment and cardiovascular disease. Heart [Internet]. 2004 [cited 2021 Oct 14];90:829\u201330. Available from: https:\/\/heart.bmj.com\/lookup\/doi\/https:\/\/doi.org\/10.1136\/hrt.2003.031492","DOI":"10.1136\/hrt.2003.031492"},{"key":"770_CR45","doi-asserted-by":"publisher","unstructured":"Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med [Internet]. 2004 [cited 2021 Oct 14];141:764. Available from: http:\/\/annals.org\/article.aspx?doi=https:\/\/doi.org\/10.7326\/0003-4819-141-10-200411160-00007","DOI":"10.7326\/0003-4819-141-10-200411160-00007"},{"key":"770_CR46","doi-asserted-by":"publisher","unstructured":"Kremers HM, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum [Internet]. 2007 [cited 2021 Oct 14];57:279\u201386. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/art.22548","DOI":"10.1002\/art.22548"},{"key":"770_CR47","doi-asserted-by":"publisher","unstructured":"Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. Rahimi K, editor. PLoS Med [Internet]. 2020 [cited 2021 Oct 14];17:e1003432. Available from: https:\/\/dx.plos.org\/https:\/\/doi.org\/10.1371\/journal.pmed.1003432","DOI":"10.1371\/journal.pmed.1003432"},{"key":"770_CR48","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/ard.2005.047498","volume":"65","author":"E Seyahi","year":"2006","unstructured":"Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis. 2006;65:1202\u20137.","journal-title":"Ann Rheum Dis"},{"key":"770_CR49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.12998\/wjcc.v3.i6.484","volume":"3","author":"C Ponte","year":"2015","unstructured":"Ponte C, Rodrigues AF, O\u2019Neill L, et al. Giant cell arteritis: current treatment and management. World J Clin Cases. 2015;3:484\u201394.","journal-title":"World J Clin Cases"},{"key":"770_CR50","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.55.7.481","volume":"55","author":"SL Johnston","year":"2002","unstructured":"Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55:481\u20136.","journal-title":"J Clin Pathol"},{"key":"770_CR51","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.48.8.658","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48:658\u201361.","journal-title":"Ann Rheum Dis."},{"key":"770_CR52","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/modpathol.2017.10","volume":"30","author":"JJ Maleszewski","year":"2017","unstructured":"Maleszewski JJ, Younge BR, Fritzlen JT, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017;30:788\u201396.","journal-title":"Mod Pathol"},{"key":"770_CR53","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/annrheumdis-2018-213488","volume":"77","author":"R Conway","year":"2018","unstructured":"Conway R, O\u2019Neill L, McCarthy GM, et al. Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis. Ann Rheum Dis. 2018;77:1815\u201324.","journal-title":"Ann Rheum Dis"},{"key":"770_CR54","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","volume":"137","author":"H Zhang","year":"2018","unstructured":"Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137:1934\u201348.","journal-title":"Circulation"},{"key":"770_CR55","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1136\/annrheumdis-2016-210792","volume":"76","author":"E Planas-Rigol","year":"2017","unstructured":"Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, et al. Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. Ann Rheum Dis. 2017;76:1624\u201334.","journal-title":"Ann Rheum Dis"},{"key":"770_CR56","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2017.02.006","volume":"16","author":"A R\u00e9gent","year":"2017","unstructured":"R\u00e9gent A, Ly KH, Groh M, et al. Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation. Autoimmun Rev. 2017;16:398\u2013406.","journal-title":"Autoimmun Rev"},{"key":"770_CR57","doi-asserted-by":"crossref","unstructured":"Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. International Journal of Cardiology [Internet]. 2000 [cited 2021 Oct 10];75:S9\u201315. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527300001984","DOI":"10.1016\/S0167-5273(00)00198-4"},{"key":"770_CR58","doi-asserted-by":"publisher","unstructured":"Crotti C, Agape E, Becciolini A, et al. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs [Internet]. 2019 [cited 2021 Oct 10];79:1741\u201355. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s40265-019-01192-z","DOI":"10.1007\/s40265-019-01192-z"},{"key":"770_CR59","doi-asserted-by":"publisher","first-page":"587089","DOI":"10.3389\/fimmu.2020.587089","volume":"11","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Berry GJ, Liang DH, et al. Cellular signaling pathways in medium and large vessel vasculitis. Front Immunol. 2020;11:587089.","journal-title":"Front Immunol."},{"key":"770_CR60","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789\u201397.","journal-title":"Arthritis Rheum"},{"key":"770_CR61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"770_CR62","doi-asserted-by":"publisher","unstructured":"Bhatia A. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Annals of the Rheumatic Diseases [Internet]. 2005 [cited 2021 Aug 4];64:1099\u2013100. Available from: https:\/\/ard.bmj.com\/lookup\/doi\/https:\/\/doi.org\/10.1136\/ard.2005.036533","DOI":"10.1136\/ard.2005.036533"},{"key":"770_CR63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/BOR.0b013e32833ee946","volume":"23","author":"CM Weyand","year":"2011","unstructured":"Weyand CM, Younge BR, Goronzy JJ. IFN-\u03b3 and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23:43\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"770_CR64","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","volume":"81","author":"K-H Ly","year":"2014","unstructured":"Ly K-H, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais A-L. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine. 2014;81:76\u20138.","journal-title":"Joint Bone Spine"},{"key":"770_CR65","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69:837\u201345.","journal-title":"Arthritis Rheumatol"},{"key":"770_CR66","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/ard.2007.070805","volume":"67","author":"E Lozano","year":"2008","unstructured":"Lozano E, Segarra M, Garc\u00eda-Mart\u00ednez A, Hern\u00e1ndez-Rodr\u00edguez J, Cid MC. Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis. 2008;67:1581\u20138.","journal-title":"Ann Rheum Dis"},{"key":"770_CR67","doi-asserted-by":"publisher","unstructured":"Taimen K, Heino S, Kohonen I, Relas H, Huovinen R, H\u00e4nninen A, et al. Granulocyte colony-stimulating factor- and chemotherapy-induced large-vessel vasculitis: six patient cases and a systematic literature review. Rheumatology Advances in Practice [Internet]. 2020 [cited 2021 Aug 4];4:rkaa004. Available from: https:\/\/academic.oup.com\/rheumap\/article\/doi\/https:\/\/doi.org\/10.1093\/rap\/rkaa004\/5728647","DOI":"10.1093\/rap\/rkaa004\/5728647"},{"key":"770_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaut.2018.07.013","volume":"94","author":"A Maciejewski-Duval","year":"2018","unstructured":"Maciejewski-Duval A, Comarmond C, Leroyer A, Zaidan M, Le Joncour A, Desbois AC, et al. mTOR pathway activation in large vessel vasculitis. J Autoimmun. 2018;94:99\u2013109.","journal-title":"J Autoimmun"},{"key":"770_CR69","doi-asserted-by":"crossref","unstructured":"Hadjadj J, Canaud G, Mirault T, Samson M, Bruneval P, R\u00e9gent A, et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. Rheumatology [Internet]. 2018 [cited 2021 Aug 4];57:1011\u201320. Available from: https:\/\/academic.oup.com\/rheumatology\/article\/57\/6\/1011\/4913314","DOI":"10.1093\/rheumatology\/key017"},{"key":"770_CR70","doi-asserted-by":"crossref","unstructured":"Wen Z, Shen Y, Berry G, et al. The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway. Sci Transl Med. 2017;9.","DOI":"10.1126\/scitranslmed.aal3322"},{"key":"770_CR71","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","volume":"48","author":"R Conway","year":"2018","unstructured":"Conway R, O\u2019Neill L, Gallagher P, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48:523\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"770_CR72","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","volume":"42","author":"AG Solimando","year":"2016","unstructured":"Solimando AG, Ribatti D, Vacca A, et al. Targeting B-cell non Hodgkin lymphoma: new and old tricks. Leuk Res. 2016;42:93\u2013104. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.001.","journal-title":"Leuk Res"},{"issue":"1","key":"770_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/ard.2011.153007","volume":"71","author":"BF Hoyer","year":"2012","unstructured":"Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71(1):75\u20139. https:\/\/doi.org\/10.1136\/ard.2011.153007.","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00770-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00770-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00770-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T03:28:50Z","timestamp":1666582130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00770-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,6]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00770-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2021,11,6]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}